Skip to content
Quebec News Tribune – Lifestyle
Author:
ABBISKO THERAPEUTICS
PIMJETMI® (pimicotinib) Developed by Abbisko Therapeutics and Licensed by Merck KGaA, Darmstadt, Germany Receive U.S. FDA Approval for TGCT
November 10, 2026